Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851384 | 0.82 | F10 (0.57) | F10MAP4K4F2PRSS1PRSS2 | |
| SCHEMBL6579300 | 0.81 | MAP4K4 (0.62) | F10MAP4K4F2SYKEGLN1 | |
| SCHEMBL6576385 | 0.80 | F10 (0.64) | F10MAP4K4F2EGLN1HRH3 | |
| SCHEMBL6576129 | 0.79 | F10 (0.65) | F10MAP4K4F2SYKEGLN1 | |
| SCHEMBL1307835 | 0.78 | MAP4K4 (0.47) | MAP4K4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6579785 | 0.78 | MAP4K4 (0.47) | F10MAP4K4SYKEGLN1HRH3 | |
| SCHEMBL6580940 | 0.77 | F10 (0.67) | F10MAP4K4F2SYKEGLN1 | |
| SCHEMBL6580977 | 0.76 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6577317 | 0.76 | MAP4K4 (0.56) | F10MAP4K4F2PRSS1PRSS2 | |
| SCHEMBL20982676 | 0.75 | NR4A1 (0.59) | MAP4K4PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-0813525-B1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6479485-B2 | 4-HYDROXY-3-((3,4-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; INHIBITION OF BLOOD COAGGULATION FACTOR XA | BERLEX LABORATORIES, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465459-B2 | INHIBIT THE ENZYME, FACTOR XA | BERLEX LABORATORIES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-14 | — | — | US | disclosed |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-07 | — | — | US | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-6306884-B1 | ANTICOAGULANTS AND BLOOD COAGULATION FACTOR | BERLEX LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6034103-A | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6004981-A | HUMAN FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 1999-12-21 | — | — | US | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5877181-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | F10 44/4885MAP4K4 1870/4885F2 4/4885 |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | F10 44/4885MAP4K4 1870/4885F2 4/4885 |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | F10 49/4885MAP4K4 1978/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.